Announcement of new appointment of the Company's
Remuneration Committee.
Date of events
2022/07/15
To which item it meets
paragraph 6
Statement
1.Date of occurrence of the change:2022/07/15
2.Name of the functional committees:Remuneration Committee
3.Name of the previous position holder:NA
4.Resume of the previous position holder:NA
5.Name of the new position holder: Jang-Yang Chang
6.Resume of the new position holder:Director, Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, Taiwan
7.Circumstances of change (Please enter "resignation", "dismissal",
"term expired", "death" or "new appointment"):new appointment
8.Reason for the change:For filling the vacancy of the Remuneration Committee
9.Original term (from __________ to __________):2021/08/27~2024/08/26
10.Effective date of the new member:2022/07/15
11.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 15 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2022 09:33:03 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.